Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Cash from Restructuring (2016)

Historic Cash from Restructuring for Harvard Bioscience (HBIO) over the last 6 years, with Q3 2016 value amounting to -$27000.0.

  • Harvard Bioscience's Cash from Restructuring fell 8000.0% to -$27000.0 in Q3 2016 from the same period last year, while for Dec 2017 it was -$27000.0, marking a year-over-year change of 0.0%. This contributed to the annual value of -$27000.0 for FY2016, which is 6823.53% up from last year.
  • According to the latest figures from Q3 2016, Harvard Bioscience's Cash from Restructuring is -$27000.0, which was down 8000.0% from -$6000.0 recorded in Q4 2015.
  • Over the past 5 years, Harvard Bioscience's Cash from Restructuring peaked at $95000.0 during Q3 2013, and registered a low of -$102000.0 during Q1 2014.
  • Its 4-year average for Cash from Restructuring is -$25272.7, with a median of -$21000.0 in 2013.
  • Its Cash from Restructuring has fluctuated over the past 5 years, first skyrocketed by 3043.48% in 2014, then crashed by 65000.0% in 2015.
  • Harvard Bioscience's Cash from Restructuring (Quarter) stood at -$97000.0 in 2013, then surged by 97.94% to -$2000.0 in 2014, then tumbled by 200.0% to -$6000.0 in 2015, then crashed by 350.0% to -$27000.0 in 2016.
  • Its Cash from Restructuring was -$27000.0 in Q3 2016, compared to -$6000.0 in Q4 2015 and -$15000.0 in Q3 2015.